Analisis Keterampilan Proses Sains melalui Self-assessment dan Peer-assessment di Kelas XI IPA SMA

The aim of this study was to describe the senior secondary student's science process skills in acid-base titration practical work. The study was conducted as a descriptive design and used survey method. Self-assessment and peer-assessment questionnaire and structured interview were used as the data collector. The population in this study were eleventh grade students of science class III and IV SMA Negeri 5 Pontianak. Simple random sampling technique was used as the sample taker technique. 28 second year students of science class IV were chosen as the samples. The results showed that observing (55,36%) interpreting (71,43%) communicating (86,90%), designing experiment (64,29%), and using instrument (74,05%). The results also showed high persentage rate of basic (lower order) science process skills (71,23%) as compared to the integrated (higher order) science process skills (69,17%)

UPAYA MENINGKATKAN HASIL BELAJAR KIMIA MELALUI PENERAPAN MODEL PEMBELAJARAN BERBASIS PERORANGAN DALAM REGU DI KELAS XI MIA SMA NEGERI 10 PALEMBANG

Upaya Meningkatkan Hasil Belajar Kimia Melalui Penerapan Model Pembelajaran Berbasis Perorangan Dalam Regu Di Kelas XI MIA SMA Negeri 10 Palembang. Penelitian tindakan kelas ini bertujuan untuk memperbaiki proses pembelajaran kimia sehingga dapat meningkatkan hasil belajar kimia siswa XI MIA 4 SMAN 10 Palembang melalui penerapan model pembelajaran TAI. Penelitian ini dilakukan dalam tiga siklus dan setiap siklus terdiri dari dua pertemuan. Pengumpulan data dilakukan dengan menggunakan tes hasil belajar dan lembar observasi kegiatan siswa setiap akhir siklus. Ketuntasan hasil belajar kimia sebelum tindakan (T0) sebesar 37,5% dan skor rata-rata 71,22. Pada siklus 1 (T1)ketuntasan belajar siswa meningkat menjadi 47,06 % dengan skor rata-rata 66,88. Hal ini disebabkan penerapan model pembelajaran TAI yang mempunyai ciri belajar bersama dengan teman, belajar dari teman sendiri dalam kelompok, dan saling mengemukakan pendapat. Pada siklus 2 (T2), ketuntasan dan skor rata-rata siswa meningkat menjadi 69,23% dan 77,17. Peningkatan ini terjadi karena siswa berdiskusi dan menjawab pertanyaan yang diberikan. Pada siklus 3 meningkat menjadi 86,8 % dengan skor rata-rata 81,57 dan telah mencapai ketuntasan secara klasikal. Hal ini terjadi karena siswa aktif dalam bertanya dan berdiskusi, serta menjawab pertanyaan yang diberikan. Hasil belajar kimia siswa meningkat melalui penerapan model pembelajaran TAI ditunjukkan dari ketuntasan dan rata-rata hasil belajar siswa dari T3>T2>T1>T0

Epidemiology of the Diseases of Wheat under Different Strategies of Supplementary Irrigation

Wheat (Triticum aestivum L.) is one of the most important and highly productive crops grown under supplementary irrigation in the central region of Santa Fe. However, its production is limited by the presence of diseases in the main stages for yield definition. The objective of this work was to assess wheat health in response to different supplementary irrigation strategies under greenhouse and field conditions. The field experiment included three treatments: dry (D), controlled deficit irrigation (CDI), and total irrigation (TI) using the central pivot method. Disease incidence from stem elongation and severity in flag leaf and the leaf below the flag leaf were measured. Leaf area index (LAI), harvest index, air biomass, and yield components were determined. In greenhouse the treatments were TI and CDI, with evaluations similar to the field. The major leaf diseases observed were tan spot, leaf rust, and septoria leaf blotch. Significant differences in disease burden, LAI and yield components were observed in the different treatments. Under greenhouse conditions, only tan spot was observed. The results of this study indicated that the application of supplemental irrigation in wheat improved the yield, without increasing the incidence and severity of foliar diseases

Evaluation of End-of-Queue Crash Mitigation Strategies at Flagging Stations on Two-Lane Roads

Project 0-6998The objective of this research project was to identify and evaluate strategies to mitigate end-of-queue crashes at flagging stations on two-lane roads. The research team evaluated the following treatments based on feasibility and advantages of each treatment: \u2022 Install light-emitting diodes (LEDs) or a warning light on the static BE PREPARED TO STOP (BPTS) sign. \u2022 Switch to a portable changeable message sign (PCMS) in lieu of the static BPTS sign. \u2022 Use a portable traffic signal (PTS) in lieu of the flagger at flagging operations. Researchers collected speed profile data of decelerating vehicles at 18 sites across Texas for the baseline (static BPTS sign) treatment and one or more other treatments. The results did not show any meaningful differences between mean speeds of baseline treatment and the BPTS sign with LED lights, BPTS sign with a warning light, or PCMS. Differences were detected when a PTS was used in lieu of a flagger, but only a limited amount of data was available for analysis. Researchers conducted a benefit-cost analysis, which only included capital costs, operation and routine maintenance costs, and transportation costs, when available. Cost savings of utilizing PTSs in lieu of flaggers were realized in just 2 years. However, more research is needed to determine its effectiveness in reducing end-of-queue crashes at flagger stations

Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

BACKGROUND AND PURPOSE: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-Analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. METHODS: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-Analysis. RESULTS: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55-1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61-1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19-1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20-1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53-1.10]; n=115). The overall effects in the 4 CVOTs combined were: Total stroke (HRpooled, 0.96 [95% CI, 0.82-1.12]), ischemic stroke (HRpooled, 1.01 [95% CI, 0.89-1.14]), hemorrhagic stroke (HRpooled, 0.50 [95% CI, 0.30-0.83]), undetermined stroke (HRpooled, 0.86 [95% CI, 0.49-1.51]), and AF/AFL (HRpooled, 0.81 [95% CI, 0.71-0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate (P=0.01), with protection in the lowest estimated glomerular filtration rate (45 mL/min/1.73 m2]) subgroup (HRpooled, 0.50 [95% CI, 0.31-0.79]). CONCLUSIONS: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to 300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m 2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction &gt;0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years